Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Cyclic tetrapeptides from the marine strain Streptomyces sp. PNM-161a with activity against rice and yam phytopathogens.

Betancur LA, Forero AM, Romero-Otero A, Sepúlveda LY, Moreno-Sarmiento NC, Castellanos L, Ramos FA.

J Antibiot (Tokyo). 2019 Jun 26. doi: 10.1038/s41429-019-0201-0. [Epub ahead of print]

PMID:
31243345
2.

Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.

Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR, Wahner-Hendrickson AE, Forero A, Anders C, Wulf GM, Dillon P, Lynce F, Zarwan C, Erban JK, Zhou Y, Buerstatte N, Graham JR, Arora S, Dezube BJ, Telli ML.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1029. [Epub ahead of print]

3.

High frequency of toxigenic Clostridium difficile and Clostridium perfringens coinfection among diarrheic patients at health care facility-onset (HCFO) and community-onset (CO) centers in Bogotá, Colombia.

Forero AJ, Muñoz M, Camargo M, Soto-De León SC, Ríos-Chaparro DI, Birchenall C, Pinilla D, Pardo JM, Josa DF, Patarroyo MA, Ramírez JD.

Gut Pathog. 2019 Jun 3;11:27. doi: 10.1186/s13099-019-0308-7. eCollection 2019.

4.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
5.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Ann Oncol. 2019 Mar 23. pii: mdz076. doi: 10.1093/annonc/mdz076. [Epub ahead of print]

PMID:
30903140
6.

Visualization of Sequential Treatments in Metastatic Breast Cancer.

Rocque GB, Kandhare PG, Williams CP, Nakhmani A, Azuero A, Burkard ME, Forero A, Bhatia S, Kenzik KM.

JCO Clin Cancer Inform. 2019 Mar;3:1-8. doi: 10.1200/CCI.18.00095.

7.

The antitumor effects of entinostat in ovarian cancer require adaptive immunity.

Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC.

Cancer. 2018 Dec 15;124(24):4657-4666. doi: 10.1002/cncr.31761. Epub 2018 Nov 13.

PMID:
30423192
8.

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM.

N Engl J Med. 2018 Nov 1;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.

PMID:
30380386
9.

Regulation of CATSPER1 expression by the testis-determining gene SRY.

Olivares A, Hernández-Reyes A, Felix R, Forero Á, Mata-Rocha M, Hernández-Sánchez J, Santos I, Aguirre-Alvarado C, Oviedo N.

PLoS One. 2018 Oct 31;13(10):e0205744. doi: 10.1371/journal.pone.0205744. eCollection 2018.

10.

Feeding in adults with type II diabetes mellitus in three public hospitals in Cundinamarca, Colombia

Forero AY, Hernández JA, Rodríguez SM, Romero JJ, Morales GE, Ramírez GÁ.

Biomedica. 2018 Sep 1;38(3):355-362. doi: 10.7705/biomedica.v38i3.3816.

11.

Isolation of Bacillus cereus in school restaurants in Colombia

Forero AY, Galindo M, Morales GE.

Biomedica. 2018 Sep 1;38(3):338-344. doi: 10.7705/biomedica.v38i3.3802.

12.

The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

McCaw TR, Li M, Starenki D, Cooper SJ, Liu M, Meza-Perez S, Arend RC, Buchsbaum DJ, Forero A, Randall TD.

Cancer Immunol Immunother. 2019 Feb;68(2):175-188. doi: 10.1007/s00262-018-2262-5. Epub 2018 Oct 17.

PMID:
30334128
13.

Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.

Rocque GB, Williams CP, Kenzik KM, Jackson BE, Azuero A, Halilova KI, Ingram SA, Pisu M, Forero A, Bhatia S.

Cancer. 2018 Nov 1;124(21):4231-4240. doi: 10.1002/cncr.31694. Epub 2018 Oct 14.

PMID:
30317547
14.

Long Noncoding RNA Signatures Induced by Toll-Like Receptor 7 and Type I Interferon Signaling in Activated Human Plasmacytoid Dendritic Cells.

Joslyn RC, Forero A, Green R, Parker SE, Savan R.

J Interferon Cytokine Res. 2018 Sep;38(9):388-405. doi: 10.1089/jir.2018.0086.

PMID:
30230983
15.

Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.

Rocque GB, Williams CP, Jackson BE, Ingram SA, Halilova KI, Pisu M, Kenzik KM, Azuero A, Forero A, Bhatia S.

J Natl Compr Canc Netw. 2018 Sep;16(9):1084-1091. doi: 10.6004/jnccn.2018.7036.

PMID:
30181420
16.

Impact of Guideline-Discordant Treatment on Cost and Health Care Utilization in Older Adults with Early-Stage Breast Cancer.

Williams CP, Kenzik KM, Azuero A, Williams GR, Pisu M, Halilova KI, Ingram SA, Yagnik SK, Forero A, Bhatia S, Rocque GB.

Oncologist. 2019 Jan;24(1):31-37. doi: 10.1634/theoncologist.2018-0076. Epub 2018 Aug 17.

PMID:
30120157
17.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

18.

Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition.

Wielgos ME, Zhang Z, Rajbhandari R, Cooper TS, Zeng L, Forero A, Esteva FJ, Osborne CK, Schiff R, LoBuglio AF, Nozell SE, Yang ES.

Mol Cancer Ther. 2018 May;17(5):921-930. doi: 10.1158/1535-7163.MCT-17-0302. Epub 2018 Mar 28.

19.

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA.

J Natl Compr Canc Netw. 2018 Mar;16(3):310-320. doi: 10.6004/jnccn.2018.0012.

PMID:
29523670
20.

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Armand P, Bello CM, Benitez CM, Bierman PJ, Chen R, Dabaja B, Dean R, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maddocks K, Maloney DG, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Rabinovitch R, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N.

J Natl Compr Canc Netw. 2018 Mar;16(3):245-254. doi: 10.6004/jnccn.2018.0013.

PMID:
29523663
21.

Generation of a human induced pluripotent stem cell (iPSC) line from a 51-year-old female with attention-deficit/hyperactivity disorder (ADHD) carrying a duplication of SLC2A3.

Jansch C, Günther K, Waider J, Ziegler GC, Forero A, Kollert S, Svirin E, Pühringer D, Kwok CK, Ullmann R, Maierhofer A, Flunkert J, Haaf T, Edenhofer F, Lesch KP.

Stem Cell Res. 2018 Apr;28:136-140. doi: 10.1016/j.scr.2018.02.005. Epub 2018 Feb 13.

22.

The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study.

Gonzalez R, Suppes T, Zeitzer J, McClung C, Tamminga C, Tohen M, Forero A, Dwivedi A, Alvarado A.

Int J Bipolar Disord. 2018 Feb 19;6(1):5. doi: 10.1186/s40345-017-0113-5.

23.

Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates.

Koday MT, Leonard JA, Munson P, Forero A, Koday M, Bratt DL, Fuller JT, Murnane R, Qin S, Reinhart TA, Duus K, Messaoudi I, Hartman AL, Stefano-Cole K, Morrison J, Katze MG, Fuller DH.

PLoS One. 2017 Dec 21;12(12):e0189780. doi: 10.1371/journal.pone.0189780. eCollection 2017.

24.

Modulation of antitumor immunity with histone deacetylase inhibitors.

McCaw TR, Randall TD, Forero A, Buchsbaum DJ.

Immunotherapy. 2017 Dec;9(16):1359-1372. doi: 10.2217/imt-2017-0134. Review.

25.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

26.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

27.

Letter to the Editor on "Risk Factors, Outcomes, and Timing of Manipulation Under Anesthesia After Total Knee Arthroplasty".

Suárez C, Londoño S, Forero A, Bonilla GA.

J Arthroplasty. 2018 Mar;33(3):969-970. doi: 10.1016/j.arth.2017.09.044. Epub 2017 Oct 5. No abstract available.

PMID:
29107494
28.

Cadherin-13 Deficiency Increases Dorsal Raphe 5-HT Neuron Density and Prefrontal Cortex Innervation in the Mouse Brain.

Forero A, Rivero O, Wäldchen S, Ku HP, Kiser DP, Gärtner Y, Pennington LS, Waider J, Gaspar P, Jansch C, Edenhofer F, Resink TJ, Blum R, Sauer M, Lesch KP.

Front Cell Neurosci. 2017 Sep 26;11:307. doi: 10.3389/fncel.2017.00307. eCollection 2017.

29.

Evaluation of the innate immune responses to influenza and live-attenuated influenza vaccine infection in primary differentiated human nasal epithelial cells.

Forero A, Fenstermacher K, Wohlgemuth N, Nishida A, Carter V, Smith EA, Peng X, Hayes M, Francis D, Treanor J, Morrison J, Klein SL, Lane A, Katze MG, Pekosz A.

Vaccine. 2017 Oct 27;35(45):6112-6121. doi: 10.1016/j.vaccine.2017.09.058. Epub 2017 Sep 28.

30.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

31.

Re-evaluating Strategies to Define the Immunoregulatory Roles of miRNAs.

Forero A, So L, Savan R.

Trends Immunol. 2017 Aug;38(8):558-566. doi: 10.1016/j.it.2017.06.001. Epub 2017 Jun 27. Review.

32.

Physical Activity and Sleep Quality in Breast Cancer Survivors: A Randomized Trial.

Rogers LQ, Courneya KS, Oster RA, Anton PM, Robbs RS, Forero A, McAuley E.

Med Sci Sports Exerc. 2017 Oct;49(10):2009-2015. doi: 10.1249/MSS.0000000000001327.

33.

Experience in the use of non-pneumatic anti-shock garment (NASG) in the management of postpartum haemorrhage with hypovolemic shock in the Fundación Valle Del Lili, Cali, Colombia.

Escobar MF, Füchtner CE, Carvajal JA, Nieto AJ, Messa A, Escobar SS, Monroy AM, Forero AM, Casallas JD, Granados M, Miller S.

Reprod Health. 2017 May 12;14(1):58. doi: 10.1186/s12978-017-0325-2.

34.

Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.

Turner TB, Meza-Perez S, Londoño A, Katre A, Peabody JE, Smith HJ, Forero A, Norian LA, Straughn JM Jr, Buchsbaum DJ, Randall TD, Arend RC.

Oncotarget. 2017 Jul 4;8(27):44159-44170. doi: 10.18632/oncotarget.17395.

35.

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H.

J Natl Compr Canc Netw. 2017 May;15(5):608-638.

PMID:
28476741
36.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2017 Apr;15(4):433-451.

PMID:
28404755
37.

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Olejnik J, Forero A, Deflubé LR, Hume AJ, Manhart WA, Nishida A, Marzi A, Katze MG, Ebihara H, Rasmussen AL, Mühlberger E.

J Virol. 2017 May 12;91(11). pii: e00179-17. doi: 10.1128/JVI.00179-17. Print 2017 Jun 1.

38.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

39.

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.

Forero A, Bendell JC, Kumar P, Janisch L, Rosen M, Wang Q, Copigneaux C, Desai M, Senaldi G, Maitland ML.

Invest New Drugs. 2017 Jun;35(3):298-306. doi: 10.1007/s10637-016-0420-1. Epub 2017 Jan 3.

PMID:
28050790
40.

The landscape of new drugs in lymphoma.

Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J.

Nat Rev Clin Oncol. 2017 Jun;14(6):335-346. doi: 10.1038/nrclinonc.2016.205. Epub 2016 Dec 29. Review.

41.

Genomic regulation of invasion by STAT3 in triple negative breast cancer.

McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM.

Oncotarget. 2017 Jan 31;8(5):8226-8238. doi: 10.18632/oncotarget.14153.

42.

Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody.

Dominguez GA, Condamine T, Mony S, Hashimoto A, Wang F, Liu Q, Forero A, Bendell J, Witt R, Hockstein N, Kumar P, Gabrilovich DI.

Clin Cancer Res. 2017 Jun 15;23(12):2942-2950. doi: 10.1158/1078-0432.CCR-16-1784. Epub 2016 Dec 13.

43.

Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2016 Dec 27;7(52):86803-86815. doi: 10.18632/oncotarget.13466. Erratum in: Oncotarget. 2018 Apr 10;9(27):19459.

44.

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

Visvanathan K, Fackler MS, Zhang Z, Lopez-Bujanda ZA, Jeter SC, Sokoll LJ, Garrett-Mayer E, Cope LM, Umbricht CB, Euhus DM, Forero A, Storniolo AM, Nanda R, Lin NU, Carey LA, Ingle JN, Sukumar S, Wolff AC.

J Clin Oncol. 2017 Mar;35(7):751-758. doi: 10.1200/JCO.2015.66.2080. Epub 2016 Nov 21.

45.

Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.

Morrison G, Lenkala D, LaCroix B, Ziliak D, Abramson V, Morrow PK, Forero A, Van Poznak C, Rugo HS, Nanda R, O'Donnell PH, Huang RS.

Oncotarget. 2016 Jun 21;7(25):38359-38366. doi: 10.18632/oncotarget.9521.

46.

Anomaly Detection in Host Signaling Pathways for the Early Prognosis of Acute Infection.

Wang K, Langevin S, O'Hern CS, Shattuck MD, Ogle S, Forero A, Morrison J, Slayden R, Katze MG, Kirby M.

PLoS One. 2016 Aug 17;11(8):e0160919. doi: 10.1371/journal.pone.0160919. eCollection 2016.

47.

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.

Raje NS, Faber EA Jr, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC.

Clin Cancer Res. 2016 Dec 1;22(23):5688-5695. Epub 2016 Jun 10.

48.

Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials.

Fouad MN, Acemgil A, Bae S, Forero A, Lisovicz N, Martin MY, Oates GR, Partridge EE, Vickers SM.

J Oncol Pract. 2016 Jun;12(6):556-63. doi: 10.1200/JOP.2015.008946. Epub 2016 May 17.

49.

A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.

Goy A, Forero A, Wagner-Johnston N, Christopher Ehmann W, Tsai M, Hatake K, Ananthakrishnan R, Volkert A, Vandendries E, Ogura M.

Br J Haematol. 2016 Aug;174(4):571-81. doi: 10.1111/bjh.14094. Epub 2016 Apr 22.

PMID:
27101934
50.

Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes.

Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE.

Cancer Immunol Res. 2016 May;4(5):390-9. doi: 10.1158/2326-6066.CIR-15-0243. Epub 2016 Mar 15.

Supplemental Content

Loading ...
Support Center